Purpose The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease. Methods We conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology. Results We found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations. Conclusions Quantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.
References
[1]
Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, et al. (2009) Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64: 92–97.
[2]
Sethi T (2002) Lung cancer. Introduction. Thorax 57: 992–993.
[3]
Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037–1057.
[4]
Wakelee HA, Bernardo P, Johnson DH, Schiller JH (2006) Changes in the natural history of nonsmall cell lung cancer (NSCLC)–comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 106: 2208–2217.
[5]
de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ (2007) Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 110: 1654–1664.
[6]
Jackman DM, Johnson BE (2005) Small-cell lung cancer. Lancet 366: 1385–1396.
[7]
Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta 1775: 181–232.
[8]
Mandel P, Métais P (1948) Les acides nucléiques du plasma sanguin chez l’homme. CR Acad Sci Paris 142: 241–243.
[9]
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, et al. (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59: 67–70.
[10]
Anker P, Mulcahy H, Chen XQ, Stroun M (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18: 65–73.
[11]
Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, et al. (2004) Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22: 4157–4164.
[12]
Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635: 105–117.
[13]
Sozzi G, Conte D, Leon M, Ciricione R, Roz L, et al. (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21: 3902–3908.
[14]
Zhang R, Shao F, Wu X, Ying K (2010) Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69: 225–231.
[15]
Bunn PJ Jr (2003) Early detection of lung cancer using serum RNA or DNA markers: ready for “prime time” or for validation? J Clin Oncol 21: 3891–3893.
[16]
Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, et al. (2001) Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61: 4675–4678.
[17]
Van den Berg RM, Brokx H, Vesin A, Field JK, Brambilla C, et al. (2010) Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. International journal of oncology 37: 455–461.
[18]
Metzger R, Vallbohmer D, Muller-Tidow C, Higashi H, Bollschweiler E, et al. (2009) Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer. Anticancer research 29: 1157–1162.
[19]
Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. Genome Res 6: 986–994.
[20]
Catarino R, Pereira D, Breda E, Coelho A, Matos A, et al. (2008) Oncogenic virus-associated neoplasia: a role for cyclin D1 genotypes influencing the age of onset of disease? Biochemical and biophysical research communications 370: 118–122.
[21]
Bremnes RM, Sirera R, Camps C (2005) Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49: 1–12.
[22]
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646–650.
[23]
Sozzi G, Roz L, Conte D, Mariani L, Andriani F, et al. (2005) Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 97: 1848–1850.
[24]
Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, et al. (2002) Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 8: 3761–3766.
[25]
van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, et al. (2010) Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68: 283–287.
[26]
Sozzi G, Roz L, Conte D, Mariani L, Andriani F, et al. (2009) Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 179: 69–74.
[27]
Ziegler A, Zangemeister-Wittke U, Stahel RA (2002) Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 28: 255–271.
[28]
Beau-Faller M, Gaub MP, Schneider A, Ducrocq X, Massard G, et al. (2003) Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105: 361–370.
[29]
Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ (2004) Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J (Engl) 117: 1485–1488.
[30]
Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, et al. (2005) Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 51: 113–118.
[31]
Gal S, Fidler C, Lo YM, Taylor M, Han C, et al. (2004) Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 90: 1211–1215.
[32]
Huang ZH, Li LH, Hua D (2006) Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 243: 64–70.
[33]
Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, et al. (2006) Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer 94: 1492–1495.
[34]
Catarino R, Ferreira MM, Sousa A, Rodrigues H, R M (2007) Quantification of Free Circulating Tumor DNA in Plasma as a Diagnostic Marker in Breast Cancer. Eur J Cancer Supplements 5/4: 184.
[35]
Laktionov PP, Tamkovich SN, Rykova EY, Bryzgunova OE, Starikov AV, et al. (2004) Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids 23: 879–883.
[36]
Johnson PJ, Lo YM (2002) Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 48: 1186–1193.
[37]
Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R (2006) Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52: 1833–1842.
[38]
Frattini M, Balestra D, Verderio P, Gallino G, Leo E, et al. (2005) Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients. J Clin Oncol 23: 3163–3164; author reply 3164–3165.
[39]
Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, et al. (2002) Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 50: 530–534.
[40]
Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, et al. (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64: 218–224.
[41]
Diehl F, Li M, Dressman D, He Y, Shen D, et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102: 16368–16373.
[42]
Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54: 1634–1637.
